Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting

Biochemical Pharmacology

Volumn 78, Issue 9, 2009, Pages 1139-1147

  Cassinelli, Giuliana ^a   Ronchetti, Domenica ^b   Laccabue, Diletta ^a   Mattioli, Michela ^b   Cuccuru, Giuditta ^a   Favini, Enrica ^a   Nicolini, Valentina ^a   Greco, Angela ^a   Neri, Antonino ^b   Zunino, Franco ^a   Lanzi, Cinzia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

BCMA; FGF R3; JAK2; Multiple myeloma; RPI 1

Indexed keywords

1,3 DIHYDRO 5,6 DIMETHOXY 3 [(4 HYDROPHENYL)METHYLENE] 1H INDOL 2 ONE; B CELL MATURATION ANTIGEN; CASPASE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; JANUS KINASE 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; OXINDOLE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SPERMINE SYNTHASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DOWN REGULATION; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; UPREGULATION;

APOPTOSIS; B-CELL MATURATION ANTIGEN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPRECIPITATION; JANUS KINASE 2; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 70349166732     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.023     Document Type: Article

References (50)

1. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., and Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev 7 (2007) 585-598
2. Chng W.J., Glebov O., Bergsagel P.L., and Kuehl W.M. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20 (2007) 571-596
3. Richelda R., Ronchetti D., Baldini L., Cro L., Viggiano L., Marzella R., et al. A novel chromosomal translocation t(4; 14)(p16. 3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90 (1997) 4062-4070
4. Todoerti K., Ronchetti D., Agnelli L., Castellani S., Marelli S., Deliliers G.L., et al. Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4; 14) in multiple myeloma. Br J Haematol 131 (2005) 214-218
5. Chesi M., Bergsagel P.L., and Kuehl W.M. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol 9 (2002) 288-293
6. Onwuazor O.N., Wen X.Y., Wang D.Y., Zhuang L., Masih-Khan E., Claudio J., et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 102 (2003) 772-773
7. Ronchetti D., Greco A., Compasso S., Colombo G., Dell'Era P., Otsuki T., et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20 (2001) 3553-3562
8. Mitsiades C.S., Mitsiades N.S., Richardson P.G., Munshi N.C., and Anderson K.C. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interaction between tumor cells and their local microenvironment. J Cell Biochem 101 (2007) 950-968
9. Van de Donk N.W.C.J., Lokhorst H.M., and Bloem A.C. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 19 (2005) 2177-2185
10. Bommert K., Bargou R.C., and Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 42 (2006) 1574-1580
11. Yasui H., Hideshima T., Richardson P.G., and Anderson K.C. Novel therapeutic strategies targeting growth factor signaling cascades in multiple myeloma. Br J Haematol 132 (2006) 385-397
12. Podar K., Chauhan D., and Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23 (2009) 10-24
13. Lanzi C., Cassinelli G., Pensa T., Cassinis M., Gambetta R.A., Borrello M.G., et al. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 85 (2000) 384-390
14. Lanzi C., Cassinelli G., Cuccuru G., Zaffaroni N., Supino R., Vignati S., et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 60 (2003) 1449-1459
15. Cuccuru G., Lanzi C., Cassinelli G., Pratesi G., Tortoreto M., Petrangolini G., et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96 (2004) 1006-1014
16. Petrangolini G., Cuccuru G., Lanzi C., Tortoreto M., Belluco S., Pratesi G., et al. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 72 (2006) 405-414
17. Cassinelli G., Lanzi C., Petrangolini G., Tortoreto M., Pratesi G., Cuccuru G., et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 5 (2006) 2388-2397
18. Cassinelli G., Favini E., Degl'Innocenti D., Salvi A., De Petro G., Pierotti M.A., et al. RET/PTC1-driven neoplastic transformation and pro invasive phenotype of human thyrocytes involve Met induction and β-catenin nuclear translocation. Neoplasia 11 (2009) 10-21
19. Agnelli L., Bicciato S., Mattioli M., Fabris S., Intini D., Verdelli D., et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 23 (2005) 7296-7306
20. Mattioli M., Agnelli L., Fabris S., Baldini L., Morabito F., Bicciato S., et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24 (2005) 2461-2473
21. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194 (2001) 1625-1638
22. Schadt E.E., Li C., Ellis B., and Wong W.H. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 37 (2001) 120-125
23. Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 46 (2007) 226-238
24. Ishikawa H., Tsuyama N., Liu S., Abroun S., Li F.-J., Otsuyama K.-I., et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 24 (2005) 6328-6332
25. Romagnoli M., Trichet V., David C., Clement M., Moreau P., Bataille R., et al. Significant impact of survivin on myeloma cell growth. Leukemia 21 (2007) 1070-1078
26. Podar K., Gouill S.L., Zhang J., Opferman J.T., Zorn E., Tai Y.T., et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 27 (2008) 721-731
27. Terpos E., Politou M., Viniou N., and Rahemtulla A. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma 46 (2005) 1699-1707
28. Hashimoto T., Abe M., Oshima T., et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125 (2004) 38-41
29. Novak A.J., Darce J.R., Arendt B.K., Harder B., Henderson K., Kindsvogel W., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103 (2004) 689-694
30. Kip1, proliferation and lymphomagenesis. EMBO J 26 (2007) 2562-2574
31. Ewen M.E. Where the cell cycle and histones meet. Genes Dev 14 (2000) 2265-2270
32. Hideshima T., Catley L., Raje N., Chauhan D., Podar K., Mitsiades C., et al. Inhibition of Akt induces significant downregulation of surviving and cytotoxicity in human multiple myeloma cells. Br J Haematol 138 (2007) 783-791
33. Grand E.K., Chase A.J., Heath C., Rahemtulla A., and Cross N.C.P. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18 (2004) 962-966
34. Trudel S., Li Z.H., Wei E., Wiesmann M., Chang H., Chen C., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 (2005) 2941-2948
35. Bisping G., Kropff M., Wenning D., Dreyer B., Bessonov S., Hilberg F., et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood 107 (2006) 2079-2089
36. Masih-Khan E., Trudel S., Heise C., Li Z., Paterson J., Nadeem V., et al. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 108 (2006) 3465-3471
37. Criss W.E. A review of polyamines and cancer. Turk J Med Sci 33 (2003) 195-205
38. 1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6 (2007) 128-137
39. Gilchrist M., Thorsson V., Li B., Rust A.G., Korb M., Roach J.C., et al. Systems biology approaches identify ATF3 as a negative regulator of toll-like receptor 4. Nature 441 (2006) 173-178
40. Karni R., de Stanchina E., Lowe S.W., Sinha R., Mu D., and Krainer A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14 (2007) 185-193
41. Pedranzini L., Dechow T., Berishaj M., Comenzo R., Zhou P., Azare J., et al. Pyridone 6, a pan-janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 66 (2006) 9714-9721
42. Yang M., Hase H., Legarda-Addison D., Varughese L., Seed B., and Ting A.T. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol 175 (2005) 2814-2824
43. Ryan M.C., Hering M., Peckham D., McDonagh C.F., Brown L., Kim K.M., et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 6 (2007) 3009-3018
44. Tai Y.-T., Li X.-F., Breitkreutz I., Song W., Neri P., Catley L., et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66 (2006) 6675-6682
45. O'Connor B.P., Raman V.S., Erickson L.D., Cook W.J., Weaver L.K., Ahonen C., et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199 (2004) 91-97
46. Claudio J.O., Masih-Khan E., Tang H., Goncalves J., Voralia M., Li Z.H., et al. A molecular compendium of genes expressed in multiple myeloma. Blood 100 (2002) 2175-2186
47. Le Gouill S., Podar K., Harousseau J.-L., and Anderson K.C. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 3 (2004) 107-110
48. Gómez-Benito M., Martinez-Lorenzo M.J., Anel A., Marzo I., and Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 313 (2007) 2378-2388
49. Harvey R.D., and Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 3 (2007) 639-647
50. Chen J., Lee B.H., Williams I.R., Kutok J.L., Mitsiades C.S., Duclos N., et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24 (2005) 8259-8267